Overview

Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED)

Status:
Terminated

Trial end date:
2007-04-01

Target enrollment:

Participant gender:

Summary

This is a randomized, multicenter, placebo-controlled, double-blind, parallel-group study evaluating Asmanex Twisthaler 220 mcg once daily (QD) in the evening (PM) compared with "Asmanex" Placebo QD PM for 12 weeks. Efficacy will be measured for the changes in forced expiratory volume in 1 second (FEV1) from baseline to the end of treatment period (Week 12 or end of the study).

Phase:

Phase 4

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Mometasone Furoate